Novartis AG ADR (NVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG ADR (NVS) has a cash flow conversion efficiency ratio of 0.094x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.68 Billion) by net assets ($38.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novartis AG ADR (NVS) defensive interval to measure how many days the company can operate on defensive assets alone.
Novartis AG ADR - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Novartis AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novartis AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novartis AG
MX:NVSN
|
0.094x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
0.325x |
|
Royal Bank of Canada
TO:RY
|
-0.106x |
|
Merck & Company Inc
NYSE:MRK
|
0.085x |
|
GE Vernova LLC
NYSE:GEV
|
0.344x |
|
Philip Morris International Inc
NYSE:PM
|
0.055x |
|
AstraZeneca PLC
NYSE:AZN
|
0.071x |
Annual Cash Flow Conversion Efficiency for Novartis AG ADR (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG ADR from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see NVS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $46.55 Billion | $19.24 Billion | 0.413x | +3.53% |
| 2024-12-31 | $44.13 Billion | $17.62 Billion | 0.399x | +29.11% |
| 2023-12-31 | $46.75 Billion | $14.46 Billion | 0.309x | +29.09% |
| 2022-12-31 | $59.42 Billion | $14.24 Billion | 0.240x | +7.81% |
| 2021-12-31 | $67.82 Billion | $15.07 Billion | 0.222x | -7.75% |
| 2020-12-31 | $56.67 Billion | $13.65 Billion | 0.241x | -1.79% |
| 2019-12-31 | $55.55 Billion | $13.62 Billion | 0.245x | +35.24% |
| 2018-12-31 | $78.69 Billion | $14.27 Billion | 0.181x | +6.67% |
| 2017-12-31 | $74.23 Billion | $12.62 Billion | 0.170x | +10.97% |
| 2016-12-31 | $74.89 Billion | $11.47 Billion | 0.153x | -0.67% |
| 2015-12-31 | $77.12 Billion | $11.90 Billion | 0.154x | -21.36% |
| 2014-12-31 | $70.84 Billion | $13.90 Billion | 0.196x | +10.89% |
| 2013-12-31 | $74.47 Billion | $13.17 Billion | 0.177x | -13.73% |
| 2012-12-31 | $69.22 Billion | $14.19 Billion | 0.205x | -5.50% |
| 2011-12-31 | $65.94 Billion | $14.31 Billion | 0.217x | +7.63% |
| 2010-12-31 | $69.77 Billion | $14.07 Billion | 0.202x | -4.97% |
| 2009-12-31 | $57.46 Billion | $12.19 Billion | 0.212x | +9.54% |
| 2008-12-31 | $50.44 Billion | $9.77 Billion | 0.194x | +3.88% |
| 2007-12-31 | $49.40 Billion | $9.21 Billion | 0.186x | -11.60% |
| 2006-12-31 | $41.29 Billion | $8.71 Billion | 0.211x | -13.43% |
| 2005-12-31 | $33.16 Billion | $8.08 Billion | 0.244x | +22.89% |
| 2004-12-31 | $33.92 Billion | $6.72 Billion | 0.198x | -9.04% |
| 2003-12-31 | $30.52 Billion | $6.65 Billion | 0.218x | +6.21% |
| 2002-12-31 | $28.41 Billion | $5.83 Billion | 0.205x | +18.36% |
| 2001-12-31 | $25.56 Billion | $4.43 Billion | 0.173x | -15.86% |
| 2000-12-31 | $22.52 Billion | $4.64 Billion | 0.206x | +11.91% |
| 1999-12-31 | $23.55 Billion | $4.33 Billion | 0.184x | -2.48% |
| 1998-12-31 | $22.66 Billion | $4.28 Billion | 0.189x | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more